EODData

MEMBERSHIP REGISTER LOG IN

LSE, 0HI3: Arrowhead Pharmaceuticals INC

15 Oct 2025
LAST:

38.43

CHANGE:
 2.27		OPEN:
36.21		HIGH:
38.43		ASK:
0.00		VOLUME:
1.2K
CHG(%):
6.26		PREV:
36.17		LOW:
36.21		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
15 Oct 2536.2138.4336.2138.431.2K
14 Oct 2535.0036.1734.8236.175.1K
13 Oct 2535.6736.9635.6736.514.2K
10 Oct 2535.6236.0435.1835.496.3K
09 Oct 2536.6936.9636.0036.045.8K
08 Oct 2536.9037.2036.0636.583.9K
07 Oct 2538.7638.7636.4236.558.6K
06 Oct 2536.6639.0836.5537.902.1K
03 Oct 2535.1436.0034.8835.762K
02 Oct 2535.2935.5434.7134.75586

COMPANY PROFILE

Name:Arrowhead Pharmaceuticals INC
About:Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
Address:177 East Colorado Boulevard, Pasadena, CA, United States, 91105
Website:https://arrowheadpharma.com

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:36.535.2%
MA10:36.425.5%
MA20:34.5011.4%
MA50:27.7238.6%
MA100:22.1173.8%
MA200:19.20100.2%
STO9:81.89 
STO14:90.59 
RSI14:72.79 
MTM14:6.27
ROC14:0.20 
ATR:1.55 
Week High:38.430.0%
Week Low:34.8210.4%
Month High:39.081.7%
Month Low:28.53100.2%
Year High:39.081.7%
Year Low:9.70296.0%